Boehringer Ingelheim - Recruiting 18 years or older. - An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies.
National Institutes of Health Clinical Center (CC) - Recruiting 11 years to 90 years. - Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome.
National Institutes of Health Clinical Center (CC) - Recruiting N/A or older. - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
St. Jude Children's Research Hospital - Recruiting N/A to 31 years. - A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies.
Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older. - A Phase 1 Study of an IL-2 Expressing, Attenuated Salmonella Typhimurium in Patients With Unresectable Hepatic Spread From Any Non-Hematologic Primary.
National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older. - Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members.
European Institute of Oncology - Recruiting 18 years to 70 years. - Nonmyeloablative Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies With Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression With Cyclophosphamide Administered Before and After Transplantation..